Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.

Lunde CS, Stebbins EE, Jumani RS, Hasan MM, Miller P, Barlow J, Freund YR, Berry P, Stefanakis R, Gut J, Rosenthal PJ, Love MS, McNamara CW, Easom E, Plattner JJ, Jacobs RT, Huston CD.

Nat Commun. 2019 Jun 27;10(1):2816. doi: 10.1038/s41467-019-10687-y.

2.

Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.

Jacobs RT, Lunde CS, Freund YR, Hernandez V, Li X, Xia Y, Carter DS, Berry PW, Halladay J, Rock F, Stefanakis R, Easom E, Plattner JJ, Ford L, Johnston KL, Cook DAN, Clare R, Cassidy A, Myhill L, Tyrer H, Gamble J, Guimaraes AF, Steven A, Lenz F, Ehrens A, Frohberger SJ, Koschel M, Hoerauf A, Hübner MP, McNamara CW, Bakowski MA, Turner JD, Taylor MJ, Ward SA.

J Med Chem. 2019 Mar 14;62(5):2521-2540. doi: 10.1021/acs.jmedchem.8b01854. Epub 2019 Feb 26.

3.

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.

4.

Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT).

Akama T, Zhang YK, Freund YR, Berry P, Lee J, Easom EE, Jacobs RT, Plattner JJ, Witty MJ, Peter R, Rowan TG, Gillingwater K, Brun R, Nare B, Mercer L, Xu M, Wang J, Liang H.

Bioorg Med Chem Lett. 2018 Jan 1;28(1):6-10. doi: 10.1016/j.bmcl.2017.11.028. Epub 2017 Nov 20.

5.

Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).

Li X, Hernandez V, Rock FL, Choi W, Mak YSL, Mohan M, Mao W, Zhou Y, Easom EE, Plattner JJ, Zou W, Pérez-Herrán E, Giordano I, Mendoza-Losana A, Alemparte C, Rullas J, Angulo-Barturen I, Crouch S, Ortega F, Barros D, Alley MRK.

J Med Chem. 2017 Oct 12;60(19):8011-8026. doi: 10.1021/acs.jmedchem.7b00631. Epub 2017 Sep 27.

PMID:
28953378
6.

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.

Zhang YK, Plattner JJ, Easom EE, Jacobs RT, Guo D, Freund YR, Berry P, Ciaravino V, Erve JCL, Rosenthal PJ, Campo B, Gamo FJ, Sanz LM, Cao J.

J Med Chem. 2017 Jul 13;60(13):5889-5908. doi: 10.1021/acs.jmedchem.7b00621. Epub 2017 Jun 29.

PMID:
28635296
7.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

8.

Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide.

Zhang YK, Plattner JJ, Easom EE, Akama T, Zhou Y, White WH, Defauw JM, Winkle JR, Balko TW, Cao J, Ge Z, Yang J.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3182-3186. doi: 10.1016/j.bmcl.2016.04.093. Epub 2016 May 7.

PMID:
27210432
9.

Discovery of an orally bioavailable isoxazoline benzoxaborole (AN8030) as a long acting animal ectoparasiticide.

Zhang YK, Plattner JJ, Easom EE, Zhou Y, Akama T, Bu W, White WH, Defauw JM, Winkle JR, Balko TW, Guo S, Xue J, Cao J, Zou W.

Bioorg Med Chem Lett. 2015 Dec 1;25(23):5589-93. doi: 10.1016/j.bmcl.2015.10.044. Epub 2015 Oct 23.

PMID:
26508546
10.

Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.

Zhang YK, Plattner JJ, Easom EE, Jacobs RT, Guo D, Sanders V, Freund YR, Campo B, Rosenthal PJ, Bu W, Gamo FJ, Sanz LM, Ge M, Li L, Ding J, Yang Y.

J Med Chem. 2015 Jul 9;58(13):5344-54. doi: 10.1021/acs.jmedchem.5b00678. Epub 2015 Jun 23.

11.
12.

Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents.

Akama T, Dong C, Virtucio C, Freund YR, Chen D, Orr MD, Jacobs RT, Zhang YK, Hernandez V, Liu Y, Wu A, Bu W, Liu L, Jarnagin K, Plattner JJ.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5870-3. doi: 10.1016/j.bmcl.2013.08.096. Epub 2013 Sep 6.

PMID:
24075731
13.

Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles.

Printsevskaya SS, Reznikova MI, Korolev AM, Lapa GB, Olsufyeva EN, Preobrazhenskaya MN, Plattner JJ, Zhang YK.

Future Med Chem. 2013 Apr;5(6):641-52. doi: 10.4155/fmc.13.16.

PMID:
23617428
14.

Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.

Akama T, Virtucio C, Dong C, Kimura R, Zhang YK, Nieman JA, Sharma R, Lu X, Sales M, Singh R, Wu A, Fan XQ, Liu L, Plattner JJ, Jarnagin K, Freund YR.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1680-3. doi: 10.1016/j.bmcl.2013.01.072. Epub 2013 Jan 29.

PMID:
23411072
15.

Synthesis and antibacterial evaluation of a novel tricyclic oxaborole-fused fluoroquinolone.

Li X, Zhang YK, Plattner JJ, Mao W, Alley MR, Xia Y, Hernandez V, Zhou Y, Ding CZ, Li J, Shao Z, Zhang H, Xu M.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):963-6. doi: 10.1016/j.bmcl.2012.12.045. Epub 2012 Dec 21.

PMID:
23312945
16.

Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria.

Hernandez V, Crépin T, Palencia A, Cusack S, Akama T, Baker SJ, Bu W, Feng L, Freund YR, Liu L, Meewan M, Mohan M, Mao W, Rock FL, Sexton H, Sheoran A, Zhang Y, Zhang YK, Zhou Y, Nieman JA, Anugula MR, Keramane el M, Savariraj K, Reddy DS, Sharma R, Subedi R, Singh R, O'Leary A, Simon NL, De Marsh PL, Mushtaq S, Warner M, Livermore DM, Alley MR, Plattner JJ.

Antimicrob Agents Chemother. 2013 Mar;57(3):1394-403. doi: 10.1128/AAC.02058-12. Epub 2013 Jan 7.

17.

Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.

Li X, Liu Y, Zhang YK, Plattner JJ, Baker SJ, Bu W, Liu L, Zhou Y, Ding CZ, Zhang S, Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7351-6. doi: 10.1016/j.bmcl.2012.10.075. Epub 2012 Oct 22.

PMID:
23142614
18.

Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.

Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y.

FEBS Lett. 2012 Sep 21;586(19):3410-4. doi: 10.1016/j.febslet.2012.07.058. Epub 2012 Jul 25.

19.

Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.

Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A, Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L.

J Med Chem. 2012 Apr 12;55(7):3021-6. doi: 10.1021/jm201278q. Epub 2012 Apr 3.

PMID:
22471376
20.

Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.

Duan M, Kazmierski W, Crosby R, Gartland M, Ji J, Tallant M, Wang A, Hamatake R, Wright L, Wu M, Zhang YK, Ding CZ, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2993-6. doi: 10.1016/j.bmcl.2012.02.039. Epub 2012 Feb 22.

PMID:
22425454
21.

Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.

Zhang YK, Plattner JJ, Freund YR, Easom EE, Zhou Y, Ye L, Zhou H, Waterson D, Gamo FJ, Sanz LM, Ge M, Li Z, Li L, Wang H, Cui H.

Bioorg Med Chem Lett. 2012 Feb 1;22(3):1299-307. doi: 10.1016/j.bmcl.2011.12.096. Epub 2011 Dec 28.

PMID:
22243961
22.

Boron-based drugs as antiprotozoals.

Jacobs RT, Plattner JJ, Keenan M.

Curr Opin Infect Dis. 2011 Dec;24(6):586-92. doi: 10.1097/QCO.0b013e32834c630e. Review.

PMID:
22001943
23.

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.

Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, Gaukel EG, Orr MD, Perales JB, Jenks M, Noe RA, Sligar JM, Zhang YK, Bacchi CJ, Yarlett N, Don R.

Future Med Chem. 2011 Aug;3(10):1259-78. doi: 10.4155/fmc.11.80.

PMID:
21859301
24.

SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. doi: 10.1371/journal.pntd.0001151. Epub 2011 Jun 28.

25.

Synthesis and SAR of novel benzoxaboroles as a new class of β-lactamase inhibitors.

Xia Y, Cao K, Zhou Y, Alley MR, Rock F, Mohan M, Meewan M, Baker SJ, Lux S, Ding CZ, Jia G, Kully M, Plattner JJ.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2533-6. doi: 10.1016/j.bmcl.2011.02.024. Epub 2011 Feb 12.

PMID:
21392987
26.

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2048-54. doi: 10.1016/j.bmcl.2011.02.006. Epub 2011 Feb 23.

PMID:
21353550
27.

Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents.

Ding D, Meng Q, Gao G, Zhao Y, Wang Q, Nare B, Jacobs R, Rock F, Alley MR, Plattner JJ, Chen G, Li D, Zhou H.

J Med Chem. 2011 Mar 10;54(5):1276-87. doi: 10.1021/jm101225g. Epub 2011 Feb 15.

PMID:
21322634
28.

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents.

Zhang YK, Plattner JJ, Freund YR, Easom EE, Zhou Y, Gut J, Rosenthal PJ, Waterson D, Gamo FJ, Angulo-Barturen I, Ge M, Li Z, Li L, Jian Y, Cui H, Wang H, Yang J.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):644-51. doi: 10.1016/j.bmcl.2010.12.034. Epub 2010 Dec 10.

PMID:
21195617
29.

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.

Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7317-22. doi: 10.1016/j.bmcl.2010.10.071. Epub 2010 Oct 21.

PMID:
21067923
30.

Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.

Li X, Zhang YK, Liu Y, Zhang S, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Liu L, Bu W, Kazmierski WM, Wright LL, Smith GK, Jarvest RL, Duan M, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7493-7. doi: 10.1016/j.bmcl.2010.10.007. Epub 2010 Oct 30.

PMID:
21041080
31.

Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.

Li X, Zhang YK, Liu Y, Ding CZ, Zhou Y, Li Q, Plattner JJ, Baker SJ, Zhang S, Kazmierski WM, Wright LL, Smith GK, Grimes RM, Crosby RM, Creech KL, Carballo LH, Slater MJ, Jarvest RL, Thommes P, Hubbard JA, Convery MA, Nassau PM, McDowell W, Skarzynski TJ, Qian X, Fan D, Liao L, Ni ZJ, Pennicott LE, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5695-700. doi: 10.1016/j.bmcl.2010.08.022. Epub 2010 Aug 10.

PMID:
20801653
32.

Discovery of novel benzoxaborole-based potent antitrypanosomal agents.

Ding D, Zhao Y, Meng Q, Xie D, Nare B, Chen D, Bacchi CJ, Yarlett N, Zhang YK, Hernandez V, Xia Y, Freund Y, Abdulla M, Ang KH, Ratnam J, McKerrow JH, Jacobs RT, Zhou H, Plattner JJ.

ACS Med Chem Lett. 2010 Apr 6;1(4):165-9. doi: 10.1021/ml100013s. eCollection 2010 Jul 8.

33.

Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.

Li X, Zhang YK, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, Fan D, Liao L, Ni ZJ, White GV, Mordaunt JE, Lazarides LX, Slater MJ, Jarvest RL, Thommes P, Ellis M, Edge CM, Hubbard JA, Somers D, Rowland P, Nassau P, McDowell B, Skarzynski TJ, Kazmierski WM, Grimes RM, Wright LL, Smith GK, Zou W, Wright J, Pennicott LE.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3550-6. doi: 10.1016/j.bmcl.2010.04.129. Epub 2010 May 20.

PMID:
20493689
34.

Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.

Zhang YK, Plattner JJ, Akama T, Baker SJ, Hernandez VS, Sanders V, Freund Y, Kimura R, Bu W, Hold KM, Lu XS.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2270-4. doi: 10.1016/j.bmcl.2010.02.010. Epub 2010 Feb 6.

PMID:
20188549
35.

Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.

Seiradake E, Mao W, Hernandez V, Baker SJ, Plattner JJ, Alley MR, Cusack S.

J Mol Biol. 2009 Jul 10;390(2):196-207. doi: 10.1016/j.jmb.2009.04.073. Epub 2009 May 6.

PMID:
19426743
36.

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32. doi: 10.1016/j.bmcl.2009.03.007. Epub 2009 Mar 9.

PMID:
19303290
37.

In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, Hold KM, Akama T, Zhang YK, Plattner JJ, Maibach HI.

J Pharm Sci. 2007 Oct;96(10):2622-31.

PMID:
17621679
38.

Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.

Maples KR, Wheeler C, Ip E, Plattner JJ, Chu D, Zhang YK, Preobrazhenskaya MN, Printsevskaya SS, Solovieva SE, Olsufyeva EN, Heine H, Lovchik J, Lyons CR.

J Med Chem. 2007 Jul 26;50(15):3681-5. Epub 2007 Jul 3.

PMID:
17608397
39.

An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.

Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang YK, Hernandez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S, Alley MR.

Science. 2007 Jun 22;316(5832):1759-61.

40.

N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin. II. Antibacterial activity of N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin.

Plattner JJ, Chu D, Mirchink EP, Isakova EB, Preobrazhenskaya MN, Olsufyeva EN, Miroshnikova OV, Printsevskaya SS.

J Antibiot (Tokyo). 2007 Apr;60(4):245-50.

PMID:
17456974
42.

Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases.

Baker SJ, Akama T, Zhang YK, Sauro V, Pandit C, Singh R, Kully M, Khan J, Plattner JJ, Benkovic SJ, Lee V, Maples KR.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5963-7. Epub 2006 Sep 25.

PMID:
16997550
43.

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ.

J Med Chem. 2006 Jul 27;49(15):4447-50.

PMID:
16854048
44.

Synthesis and antibacterial activity of C12 des-methyl ketolides.

Lin X, Rico AC, Chu DT, Carroll GL, Barker L, Shawar R, Desai MC, Plattner JJ.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4692-6. Epub 2006 Jun 19.

PMID:
16784845
45.

Synthesis and antibacterial activity of novel C12 ethyl ketolides.

Burger MT, Hiebert C, Seid M, Chu DT, Barker L, Langhorne M, Shawar R, Kidney J, Desai MC, Plattner JJ.

Bioorg Med Chem. 2006 Aug 15;14(16):5592-604. Epub 2006 May 11.

PMID:
16697203
46.

Synthesis and antibacterial activity of novel C12 vinyl ketolides.

Burger MT, Lin X, Chu DT, Hiebert C, Rico AC, Seid M, Carroll GL, Barker L, Huh K, Langhorne M, Shawar R, Kidney J, Young K, Anderson S, Desai MC, Plattner JJ.

J Med Chem. 2006 Mar 9;49(5):1730-43.

PMID:
16509588
47.

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.

Sham HL, Betebenner DA, Rosenbrook W, Herrin T, Saldivar A, Vasavanonda S, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2004 May 17;14(10):2643-5.

PMID:
15109669
48.

In vivo characterization of A-192411: a novel fungicidal lipopeptide (II).

Meulbroek JA, Nilius AM, Li Q, Wang W, Hasvold L, Steiner B, Dickman DA, Ding H, Frost D, Goldman RC, Lartey P, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):495-7.

PMID:
12565958
49.

Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I).

Wang W, Li Q, Hasvold L, Steiner B, Dickman DA, Ding H, Clairborne A, Chen HJ, Frost D, Goldman RC, Marsh K, Hui YH, Cox B, Nilius A, Balli D, Lartey P, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):489-93.

PMID:
12565957
50.

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

Sham HL, Zhao C, Li L, Betebenner DA, Saldivar A, Vasavanonda S, Kempf DJ, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3101-3.

PMID:
12372511

Supplemental Content

Loading ...
Support Center